The effect of N-acetyl cysteine injection on renal function after coronary artery bypass graft surgery: a randomized double blind clinical trial.
Acetylcysteine
/ therapeutic use
Acute Kidney Injury
/ diagnosis
Adult
Aged
Antioxidants
/ therapeutic use
Coronary Artery Bypass
Double-Blind Method
Drug Administration Schedule
Female
Humans
Injections, Intravenous
Kidney Function Tests
Male
Middle Aged
Perioperative Care
/ methods
Postoperative Complications
/ diagnosis
Treatment Outcome
Acute kidney injury
Coronary artery bypass graft surgery
N-acetyl-cysteine
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
05 Jun 2021
05 Jun 2021
Historique:
received:
19
04
2021
accepted:
25
05
2021
entrez:
6
6
2021
pubmed:
7
6
2021
medline:
9
7
2021
Statut:
epublish
Résumé
This study aimed to compare the effects of N-acetyl cysteine on renal function after coronary artery bypass graft surgery. In this randomized clinical trial conducted in Golestan Hospital, Ahvaz, Iran, 60 candidates for coronary artery bypass graft surgery were selected and divided into two N-acetyl cysteine and control groups (30 people each). Patients received 3 (2 intraoperative and 1 postoperative) doses of IV N-acetyl cysteine (100 mg/kg) (n = 30) or placebo (n = 30) over 24 h. Prescription times were as follows: after induction of anesthesia, in the Next 4 h, and in the 16 h after on. Primary outcomes were serum levels of BUN and Cr, at baseline,4 and 48 h after surgery. And also need renal replacement therapy (RRT). Secondary outcomes included the hemodynamic variables, Blood products transfusion. There were significant differences in BUN between groups at 4 h (P = 0.02) and 48 h after surgery (P = 0.001) There were significant differences in Cr level between groups at 4 h (P < 0.001) and 48 h after surgery (P = 0.001). MAP at different times (at 4 h p = 0.002 and 48 h after surgery P < 0.001) were significantly different between the two groups. There was a significant difference between the two groups in terms of the unit of Packed cell transfusion (P = 0.002) and FFP transfusion (P < 0.001). In the present study, we found that administration of N-acetyl cysteine can reduce the incidence of acute kidney injury in patients undergoing coronary artery bypass graft surgery and improved kidney functions. IRCT20190506043492N3 Registered at 2020.06.07.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to compare the effects of N-acetyl cysteine on renal function after coronary artery bypass graft surgery.
METHODS
METHODS
In this randomized clinical trial conducted in Golestan Hospital, Ahvaz, Iran, 60 candidates for coronary artery bypass graft surgery were selected and divided into two N-acetyl cysteine and control groups (30 people each). Patients received 3 (2 intraoperative and 1 postoperative) doses of IV N-acetyl cysteine (100 mg/kg) (n = 30) or placebo (n = 30) over 24 h. Prescription times were as follows: after induction of anesthesia, in the Next 4 h, and in the 16 h after on. Primary outcomes were serum levels of BUN and Cr, at baseline,4 and 48 h after surgery. And also need renal replacement therapy (RRT). Secondary outcomes included the hemodynamic variables, Blood products transfusion.
RESULTS
RESULTS
There were significant differences in BUN between groups at 4 h (P = 0.02) and 48 h after surgery (P = 0.001) There were significant differences in Cr level between groups at 4 h (P < 0.001) and 48 h after surgery (P = 0.001). MAP at different times (at 4 h p = 0.002 and 48 h after surgery P < 0.001) were significantly different between the two groups. There was a significant difference between the two groups in terms of the unit of Packed cell transfusion (P = 0.002) and FFP transfusion (P < 0.001).
CONCLUSION
CONCLUSIONS
In the present study, we found that administration of N-acetyl cysteine can reduce the incidence of acute kidney injury in patients undergoing coronary artery bypass graft surgery and improved kidney functions.
TRIAL REGISTRY
BACKGROUND
IRCT20190506043492N3 Registered at 2020.06.07.
Identifiants
pubmed: 34090464
doi: 10.1186/s13019-021-01550-7
pii: 10.1186/s13019-021-01550-7
pmc: PMC8180023
doi:
Substances chimiques
Antioxidants
0
Acetylcysteine
WYQ7N0BPYC
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
161Subventions
Organisme : Ahvaz Jundishapur University of Medical Sciences
ID : PAIN-9817
Références
Ann Thorac Surg. 2000 Jul;70(1):84-90
pubmed: 10921687
Braz J Cardiovasc Surg. 2017 Jan-Feb;32(1):8-14
pubmed: 28423123
Int J Ayurveda Res. 2010 Jan;1(1):55-7
pubmed: 20532100
Nephrology (Carlton). 2015 Feb;20(2):96-102
pubmed: 25384603
Ann Transl Med. 2019 Feb;7(3):44
pubmed: 30906748
Annu Rev Pharmacol Toxicol. 2008;48:463-93
pubmed: 17937594
Nutr J. 2016 Jul 25;15(1):71
pubmed: 27456681
NDT Plus. 2008 Dec;1(6):392-402
pubmed: 28657002
Kidney Int. 2020 Aug;98(2):294-309
pubmed: 32709292
J Int Soc Sports Nutr. 2005 Dec 09;2:38-44
pubmed: 18500954
Anatol J Cardiol. 2016 Jul;16(7):504-511
pubmed: 27004703
Antioxid Redox Signal. 2016 Jul 20;25(3):119-46
pubmed: 26906267
Oxid Med Cell Longev. 2015;2015:189863
pubmed: 25722792
JAMA. 2005 Jul 20;294(3):342-50
pubmed: 16030279
Braz J Cardiovasc Surg. 2018 Mar-Apr;33(2):129-134
pubmed: 29898141
Clin J Am Soc Nephrol. 2008 Nov;3(6):1610-4
pubmed: 18667743
Am J Kidney Dis. 2010 Oct;56(4):643-50
pubmed: 20541301
Int J Cardiol. 2016 Apr 15;209:319-27
pubmed: 26922293
Antioxidants (Basel). 2019 Apr 28;8(5):
pubmed: 31035402
Ann Card Anaesth. 2016 Oct-Dec;19(4):687-698
pubmed: 27716701
Nephrology (Carlton). 2007 Oct;12(5):510-3
pubmed: 17803476
Curr Med Res Opin. 2005 Aug;21(8):1161-4
pubmed: 16083524
J Intensive Care. 2018 Aug 13;6:48
pubmed: 30123509
J Am Heart Assoc. 2016 Sep 23;5(9):
pubmed: 27663415
Cell J. 2017 Apr-Jun;19(1):11-17
pubmed: 28367412
Clin Cardiol. 2014 Feb;37(2):108-14
pubmed: 24672814